Clinical trials: Gastric Atrophy
Intestinal Metaplasia, Gastric Cancer
Gastric Cancer Precursor Lesions (GCPL) Study
Background: Gastric cancer is a leading cause of cancer deaths around the world. This disease is a serious problem in places like East Asia, Central and South America, and Eastern Europe.
- Trial name
- NCT03188406
- Where
- 9 sites in Chile
- Volunteers
- 1,300 people
- Sponsor
- National Cancer Institute (NCI)
TCM Syndrome of Chronic Atrophic Gastritis
Syndrome Patterns for Chronic Atrophic Gastritis Malignant Transformation
Chronic atrophic gastritis (CAG) is acknowledged as the precancerous stage of gastric cancer (GC). The present study aims to explore Traditional Chinese Medicine (TCM) syndrome features in different stages of CAG malignant…
- Trial name
- NCT03314038
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Beijing University of Chinese Medicine
Functional Dyspepsia, Chronic Atrophic Gastritis (CAG)
Correlation Study of Atrophic Gastritis and Dyspepsia Symptoms
Background: Dyspepsia is a common gastrointestinal complaint globally, affecting approximately 21.8% of the population. Among patients presenting with dyspeptic symptoms, over 80% are diagnosed with functional dyspepsia (FD)…
- Trial name
- NCT07250308
- Where
- China
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- The Third Affiliated hospital of Zhejiang Chinese Medical University
Chronic Atrophic Gastritis
The Study of Chinese Medicine for the Treatment of Chronic Atrophic Gastritis
The purpose of this study is to evaluate efficacy of Chinese medicine treatment for chronic atrophic gastritis. It is a multi-center, randomized, placebo-controlled trial.
- Trial name
- NCT02955134
- Testing
- Talcid®, Chinese medicine prescription, Compound Azimtamide Entieric-coated Tablets
- Where
- 13 sites in China
- Volunteers
- 468 people
- Sponsor
- Wangjing Hospital, China Academy of Chinese Medical Sciences
Stomach Neoplasms, Atrophic Gastritis
OLGA and OLGIM Stage System for Gastric Cancer
To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification in South Korea.
- Conditions
- Stomach Neoplasms, Atrophic Gastritis, Intestinal Metaplasia
- Trial name
- NCT03380052
- Where
- South Korea
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Atrophic Gastritis, Artificial Intelligence
AI-assisted White Light Endoscopy to Identify the Kimura-Takemoto Classification of Atrophic Gastritis
Grading endoscopic atrophy according to the Kimura-Takemoto classification can assess the risk of gastric neoplasia development.
- Conditions
- Atrophic Gastritis, Artificial Intelligence, Endoscopy
- Trial name
- NCT05916014
- Testing
- Diagnostic Test: The diagnosis of Artificial Intelligence and endosopists
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Shandong University
Colorectal Cancer, Colorectal Adenoma
Volatile Markers in Digestive Cancer
The study is aimed to determine the potential of volatile marker testing for identification of gastrointestinal cancers (in particular - colorectal and gastric cancers), the related precancerous lesions in the stomach and colon.
- Conditions
- Colorectal Cancer, Colorectal Adenoma, Gastric Cancer, Peptic Ulcer Disease
- Trial name
- VOLGACORE (NCT02332213)
- Testing
- Breath sampling for volatile marker detection, Upper endoscopy with biopsies, Colonoscopy with biopsies or lesion removal when required
- Where
- 2 sites in Latvia, Lithuania
- Volunteers
- 2,022 people, healthy volunteers welcome
- Sponsor
- University of Latvia
Gastric Cancer, Non-Atrophic Gastritis
Helicobacter Pylori Genome Project (HpGP)
Helicobacter pylori is a common bacterial infection. It can lead to severe stomach problems, including stomach cancer. Researchers want to look at samples of the bacteria. These H.
- Conditions
- Gastric Cancer, Non-Atrophic Gastritis, Intestinal Metaplasia
- Trial name
- NCT02788214
- Where
- 94 sites in United States, Algeria and 51 more
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Atrophic Gastritis, Hypergastrinaemia
YF476 and Type I Gastric Carcinoids
The aim of the study is to find out if the experimental medicine, YF476, can make gastric carcinoids, a rare type of stomach tumour, shrink and disappear.
- Conditions
- Chronic Atrophic Gastritis, Hypergastrinaemia, Type I Gastric Carcinoids
- Trial name
- NCT01339169
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Trio Medicines Ltd.
Diabetes Mellitus, Iron Metabolism Disorders
Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy
Patients who are genetically diagnosed with the recently reported and rare Wolfram syndrome type 2 ( WFS2) and have the degenerative and symptomatic disease including signs such as diabetes, platelet aggregation defect or visual…
- Conditions
- Diabetes Mellitus, Iron Metabolism Disorders, Gastroduodenal Ulcer, Optic Atrophy
- Trial name
- NCT02882477
- Testing
- Deferiprone, Acetylcysteine, Sitagliptin and Metformin
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization